Osteoporosis Treatment Market By Drug Type (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors) - Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025
Osteoporosis is a commonly observed bone disease that weakens bone and further enhance the risk of bone breaking. This condition makes bone fragile thus increasing the susceptibility of fracture. According to International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. Thus with rising prevalence of osteoporosis, number of campaigns and programs are conducted by National Osteoporosis Foundation (NOF), National Bone Health Alliance and Fracture Liaison Service (FLS) to increase in awareness about osteoporosis amongst healthcare professionals and individual, which would further propel the osteoporosis treatment market. With novel drug in pipeline, entry of generic especially in emerging economies is anticipated to boost the demand of osteoporosis treatment market in the forecast period.
The report titled “Osteoporosis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall osteoporosis treatment market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies. The drug types studied for analyzing the overall global osteoporosis treatment market are majorly segmented into bisphosphonates, parathyroid hormone therapy, calcitonin, selective estrogen inhibitors modulator (SERM) and rank ligand inhibitors.
Geographically, the global osteoporosis treatment market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year. Further cross-sectional presented in terms of drug and constituent region/country level markets is also included in this section.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global osteoporosis treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global osteoporosis treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global osteoporosis treatment market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Allergan Plc., Amgen, Inc., Actavis Plc., Eli Lilly and Company, F.Hoffmann La Roche Ltd, GlaxoSmithKline Pharmaceutical Ltd, Merck & Co AG, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd.. and others.
Based on the type of drugs, the global osteoporosis treatment market is segmented as follows:
- Bisphosphonates
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM)
- Rank Ligand Inhibitors
Bisphosphonates is the most commonly prescribed medication for prevention and treatment of osteoporosis. It occupies the major revenue share, thus dominating the global osteoporosis treatment market due to its wide consumption, attributing to high efficacy. High adoption of new drug classes such as rank ligand inhibitors and parathyroid hormone therapy, further boosts the growth of osteoporosis treatment market. With the entry of novel drug class, hurdles such as chronic and generics side effects of the established drugs will be overcome. The entry of generic drugs, especially in developing countries, will help in addressing the clinical need for low cost medication for treatment of osteoporosis, which further would exhibit lucrative growth in forecast period.
For the purpose of this study, the global osteoporosis treatment market is geographically categorized into:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
In 2016, North America dominated the global osteoporosis treatment market followed by Europe. Currently, in U.S., osteoporosis and low bone mass are considered as major public health threat affecting around 44 million U.S. women and men aged 50 and older. In Canada, osteoporosis affects approximately 1.4 million individuals, mainly postmenopausal women and the elderly. Primarily due to geriatric population, the prevalence of osteoporosis and low bone mass is expected to increase, thus driving the osteoporosis treatment market. Asia Pacific is anticipated to be the fastest growing regional market in the forecast period 2017-2025. In Asia, high portion of population with osteoporosis remains underdiagnosed and undertreated, even in the most high risk patients who have already had a fracture. This situation is commonly observed in rural areas. In developing countries such as India and China, majority of the population lives in rural areas (60% in China), home care treatment are more preferred over surgical treatment in hospitals even in case of hip fractures. But with rising awareness, improving healthcare structure, and increasing population in emerging economies will drive the growth of osteoporosis treatment market.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Osteoporosis Treatment Market Portraiture
2.1.1. Global Osteoporosis Treatment Market, by Drug Type, 2016
2.1.2. Global Osteoporosis Treatment Market, by Geography, 2016
Chapter 3. Osteoporosis Treatment: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Osteoporosis Treatment Market, by Drug Type
4.3. Bisphosphonates
4.4. Parathyroid Hormone Therapy
4.5. Calcitonin
4.6. Selective Estrogen Inhibitors Modulator (SERM)
4.7. Rank Ligand Inhibitors
Chapter 5. Global Osteoporosis Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Osteoporosis Treatment Market Analysis, 2015 – 2025
5.2.1. North America Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
5.2.2. North America Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Osteoporosis Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
5.3.2. Europe Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Rest of Europe
5.4. Asia Pacific Osteoporosis Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. India
5.4.2.4. Rest of APAC
5.5. Latin America Osteoporosis Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Osteoporosis Treatment Market Analysis, 2015 – 2025
5.6.1. MEA Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
5.6.2. MEA Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.6.2.1. UAE
5.6.2.2. Saudi Arabia
5.6.2.3. South Africa
5.6.2.4. Rest of MEA
Chapter 6. Company Profiles
6.1. Allergan Plc
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Drug Portfolio
6.1.4. Key Developments
6.2. Amgen, Inc.
6.3. Actavis Plc.
6.4. Eli Lilly and Company
6.5. F. Hoffmann La Roche Ltd.
6.6. GlaxoSmithKline Pharmaceutical Ltd.
6.7. Merck & Co AG
6.8. Novartis AG
6.9. Novo Nordisk A/S
6.10. Pfizer, Inc.
6.11. Teva Pharmaceuticals Industries Ltd.
6.12. Other Notable Players
TABLE 1 Global Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 2 North America Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 3 North America Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 4 Europe Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Asia Pacific Osteoporosis Treatment Market, by Drug Type, 2015 – 2025(US$ Mn)
TABLE 7 Asia Pacific Osteoporosis Treatment Market, by Country, 2015 – 2025(US$ Mn)
TABLE 8 Latin America Osteoporosis Treatment Market, by Drug Type, 2015 – 2025(US$ Mn)
TABLE 9 Latin America Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Middle East and Africa Osteoporosis Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Osteoporosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Allergan Plc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 13 Amgen, Inc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 14 Actavis Plc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 15 Eli Lilly and Company: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 16 F.Hoffmann La Roche Ltd: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 17 GlaxoSmithKline Pharmaceutical Ltd: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 18 Merck & Co AG: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 19 Novartis AG: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 20 Novo Nordisk A/S: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
TABLE 22 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description, Financial Information, Drug Portfolio, Key Developments)
FIG. 1 Osteoporosis Treatment : Market Segmentation
FIG. 2 Global Osteoporosis Treatment Market Share, by Drug Type, 2016 (US$ Mn)
FIG. 3 Global Osteoporosis Treatment Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Bisphosphonates Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Parathyroid Hormone Therapy Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Calcitonin Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Selective Estrogen Inhibitors Modulator (SERM) Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Rank Ligand Inhibitors Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 11 U.S. Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 12 Canada Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.K. Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Germany Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 France Osteoporosis Treatment Market, 2015-2025 (US$ Mn)
FIG. 16 Rest of Europe Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 17 Japan Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 China Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 19 India Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Rest of Asia Pacific Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Brazil Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 Mexico Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 Rest of Latin America Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 UAE Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 25 Saudi Arabia Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 26 South Africa Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Middle East and Africa Osteoporosis Treatment Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)